Identifying Risk Factors and Patterns for Early Recurrence of Pancreatic Neuroendocrine Tumors: A Multi-Institutional Study

SIMPLE SUMMARY: Approximately 30% of patients with a pancreatic neuroendocrine tumor (pNET) will develop metastases. Curative-intent treatment largely involves resection. Identifying patients with early recurrence (ER) following resection might help tailor adjuvant therapies and the surveillance int...

Descripción completa

Detalles Bibliográficos
Autores principales: Heidsma, Charlotte M., Tsilimigras, Diamantis I., Rocha, Flavio, Abbott, Daniel E., Fields, Ryan, Poultsides, George A., Cho, Clifford S., Lopez-Aguiar, Alexandra G., Kanji, Zaheer, Fisher, Alexander V., Krasnick, Bradley A., Idrees, Kamran, Makris, Eleftherios, Beems, Megan, van Eijck, Casper H. J., Nieveen van Dijkum, Elisabeth J. M., Maithel, Shishir K., Pawlik, Timothy M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8124896/
https://www.ncbi.nlm.nih.gov/pubmed/34067017
http://dx.doi.org/10.3390/cancers13092242

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8124896/
https://www.ncbi.nlm.nih.gov/pubmed/34067017
http://dx.doi.org/10.3390/cancers13092242

Ejemplares similares